Wepon Pharmaceuticals Group Co. Ltd.

Primary objective: To use Sulpiride tablets (specification: 0.1 g) developed by Wanbangde Pharmaceutical Group Co., Ltd. as the test preparation (T), and the original research and development non-imported Sulpiride tablets (trade name: Dogmatyl®, specification: 100 mg) certified by Nichiyo Co., Ltd. as the reference preparation (R), to investigate the pharmacokinetic parameters and relative bioavailability of the two preparations in the fasting and postprandial state, and to evaluate whether the two preparations are bioequivalent. Secondary objective: To compare the safety of the test preparation and reference preparation (trade name: Dogmatyl®) of Sulpiride tablets in healthy subjects.

Primary objective: To evaluate the bioequivalence of the test preparation (specification: 0.1 g; manufacturer: Wanbangde Pharmaceutical Group Co., Ltd.) and the reference preparation (English name: Norfloxacin Tablets; English trade name: BACCIDAL; specification: 0.1 g; licensee: KYORIN Pharmaceutical Co., Ltd.) in Chinese healthy subjects under fasting state, using the in vivo pharmacokinetic parameters of norfloxacin tablets as the evaluation index of bioequivalence. Secondary objective: To observe the safety of the test preparation and the reference preparation when taken orally on an empty stomach.